Science AI Journal
Neuroscience · Research topic

Open research questions in Neurological Disease Mechanisms and Treatments

52 unresolved questions extracted from the limitations and future-work sections of 214 Neurological Disease Mechanisms and Treatments papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The specific contributions of microvascular complications and glycemic control to cognitive decline remain unclear. Prior studies have shown inconsistent associations between microvascular complications and dementia risk.

    Impact of Microvascular Complication Burden on the Risk of Dementia and Cognitive Decline in Patients With Diabetes: A Systematic Review of Latest Evidence · 2026 · DOI

  • The study faced challenges in terms of image quality and motion artifact. There is a need for further research to validate the use of OCT-A as a screening biomarker. The study had to address the issue of selection bias.

    Retinal Microvascular Changes on OCT-Angiography in Preclinical Alzheimer’s Disease: A Prospective Indonesian Cohort Study · 2026 · DOI

  • Heatstroke is a complex condition with multiple pathophysiological mechanisms. The study of heatstroke is challenging due to the lack of understanding of the metabolic mechanisms involved.

    Kynurenine pathway metabolomics in heatstroke: a validated LC-MS/MS method reveals compartment-specific neurochemical disruption in a murine model. · 2026 · DOI

  • Mitochondrial dysfunction is a complex phenomenon. Limited understanding of the relationship between systemic circulating biomarkers and neuropathological mitochondrial changes in the brain.

    Mitochondrial protein alterations in vascular dementia: evidence from Mendelian randomization, transcriptomics, and a chronic hypoperfusion model · 2026 · DOI

  • The complexity of Alzheimer's disease pathology. The need for prospective APOE-stratified clinical trials. The potential for telmisartan to have off-target effects.

    Telmisartan for Apolipoprotein E ε4 Carriers as a Candidate Precision Medicine Strategy in Alzheimer’s Disease · 2026 · DOI

  • The lack of effective treatments for ischemic stroke due to the limitations of current therapies. The need for a treatment that can scavenge ROS and suppress neuroinflammation in ischemic stroke.

    Baicalin-loaded MOF-818 nanozyme for ischemic stroke treatment via ROS scavenging and neuroinflammation suppression · 2026 · DOI

  • Further clinical trials are needed to fully understand the effects of GLP-1 receptor agonists in CNS disease. The development of dual GLP-1/GIP receptor agonists with enhanced transport across the blood-brain barrier is a promising area of research. Novel strategies for getting GLP-1 receptor agonists into the brain need to be explored.

    GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease · 2026 · DOI

  • There is a large unmet need for disease-modifying therapies in CNS disease. The ability of GLP-1 receptor agonists to cross the blood-brain barrier is a key limitation. There is a need for novel strategies to get GLP-1 receptor agonists into the brain to successfully treat CNS diseases.

    GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease · 2026 · DOI

  • However, whether ischemic stroke induces retrotransposon activation remains unclear.

    Ischemia-reperfusion and acidosis induce retrotransposon derepression in the mouse brain · 2026 · DOI

  • Background: Vascular contributions to cognitive impairment and dementia (VCID) are thought to arise from distributed neurovascular unit (NVU) dysfunction rather than focal pathology, yet the transcriptional architecture of human VCID brain tissue and the status of endogenous counter-regulatory signaling within it remain incompletely characterized.

    Transcriptomic Evidence of MAS1 Receptor Dysregulation and a Failed Compensatory State in Human Vascular Cognitive Impairment · 2026 · DOI

  • The limited WM density in lissencephalic rodent models reduces translatability to clinical disease. The size and simplicity of the rodent brain make it challenging to evaluate deep WM lesions and CBF. The relative scarcity of large animal models is generally attributed to cost barriers, technical demands, and ethical considerations.

    From artery to memory: a comparative review of vascular cognitive impairment surgical models · 2026 · DOI

  • The development of large animal models with improved clinical translatability. The investigation of specific VCI subtypes using appropriate surgical models.

    From artery to memory: a comparative review of vascular cognitive impairment surgical models · 2026 · DOI

  • Challenges such as limited blood-brain barrier penetration, stability of recombinant forms, and incomplete mechanistic understanding hinder clinical translation.

    α-Klotho as a central integrative signalling hub in cognitive function and neuroprotection in neurodegenerative diseases · 2026 · DOI

  • The paper identifies a gap in the understanding of α-Klotho’s role in cognitive function and neuroprotection. It highlights the need for further research on its therapeutic potential.

    α-Klotho as a central integrative signalling hub in cognitive function and neuroprotection in neurodegenerative diseases · 2026 · DOI

  • Further studies are needed to validate the use of OCT-A as a screening biomarker for preclinical AD. Studies should investigate the relationship between OCT-A parameters and cerebral amyloid deposition. Research should focus on developing scalable and affordable screening tools for dementia.

    Retinal Microvascular Changes on OCT-Angiography in Preclinical Alzheimer’s Disease: A Prospective Indonesian Cohort Study · 2026 · DOI

  • The metabolic mechanisms linking acute injury to chronic neurological long-term effects remain understood. There is a need to better understand the pathophysiological consequences of heatstroke, particularly in vulnerable populations.

    Kynurenine pathway metabolomics in heatstroke: a validated LC-MS/MS method reveals compartment-specific neurochemical disruption in a murine model. · 2026 · DOI

  • There is a lack of understanding of the biological links between Alzheimer's disease and type 2 diabetes mellitus. There is a need for further research on the neuroprotective effects of antidiabetic drugs in Alzheimer's disease. The clinical limitations of DPP-4 inhibitors in Alzheimer's disease must be addressed through further research.

    Beyond Glycemic Control: Neuroprotective Effects of Antidiabetic Drugs in Alzheimer’s Disease · 2026 · DOI

  • trafficking, or modify The consistent pattern of APOE4-negative patients responding more favorably to antidiabetic interventions observed in trials of rosiglitazone, intranasal insulin, and INI detemir strongly suggests that APOE genotype influences pharmacological response [59, 64, 77]. APOE4 may impair GLP-1 receptor-mediated lipid signaling, alter insulin receptor inflammatory responses in ways that attenuate drug efficacy. Prospective pharmacogenomic stratification by APOE status should be mandatory in future antidiabetic AD trials. Beyond APOE4, polymorphisms in OCT1 (affecting metformin uptake), GLP1R (affecting receptor sensitivity), and PPARG (affecting TZD efficacy) are candidate pharmacogenomic variables. Incorporating these into trial stratification will enable identification of responding subpopulations, rescue trials that might otherwise show null results in unselected populations and guide personalized prescribing if regulatory approval is eventually sought. those including integrating 7.1 Drug Repurposing Strategies Antidiabetic drugs are well-positioned for systematic repurposing in AD. Network pharmacology approaches mapping drug targets onto AD molecular interaction networks have identified metformin and GLP-1 RAs as agents with high connectivity to AD-relevant disease. Computational drug-disease matching modules platforms, transcriptomic disease signatures with drug perturbation databases, have repeatedly flagged antidiabetic drugs as high-confidence repurposing candidates. These computational prioritization strategies should guide the selection and sequencing of clinical (Targeting Ageing with Metformin) trial, a landmark multicenter study evaluating in age-related condition prevention, will metformin generate foundational data on metformin's effects on aging biomarkers, cognitive trajectories, and comorbidity burden in a non-diabetic population. Its outcomes will significantly inform the design of metformin trials in preclinical AD. trials. The TAME 7.4 BBB-Targeted and Nanoparticle Drug Delivery Enhancing CNS delivery of antidiabetic drugs is a tractable research priority. Nasal lipid nanoparticle formulations of metformin have been evaluated in preclinical models, demonstrating significantly improved hippocampal drug to oral administration with concentrations compared associated improvements in cognitive and inflammatory endpoints. Solid lipid nanoparticles and polymeric nanoparticles functionalized with transferrin receptor ligands or apolipoprotein E peptides can exploit receptormediated BBB transcytosis to deliver otherwise poorly penetrant drugs to the brain parenchyma.

    Beyond Glycemic Control: Neuroprotective Effects of Antidiabetic Drugs in Alzheimer’s Disease · 2026 · DOI

  • The limited clinical efficacy of recanalization therapies underscores the need for adjunct neuroprotective strategies. The study identifies a gap in the current understanding of the therapeutic potential of Kangen-karyu for mitigating global cerebral ischemia/reperfusion-induced brain injury.

    Chinese prescription Kangen-karyu attenuates neuronal damage and improves cognitive function in global cerebral ischemia/reperfusion by regulating ROS-mediated MAPK activation · 2026 · DOI

  • There is a lack of disease-modifying therapy for vascular cognitive impairment. There is a need to elucidate the mechanisms of vascular cognitive impairment and identify suitable drugs for early intervention.

    Pentoxifylline targets TLR4/MyD88/NF-κB signaling to ameliorate neuroinflammation and metabolic dysfunction in a rat model of chronic hypoperfusion-induced vascular cognitive impairment · 2026 · DOI

  • Further investigation of the mechanisms by which cell therapy restores metabolic homeostasis. Evaluation of the potential of cell therapy to facilitate angiogenesis, synaptic plasticity, and tissue repair. Development of standardized potency assays and target-engagement biomarkers for cell therapy.

    Cell Therapy as Metabolic Rescue after Ischemic Stroke: Rewiring Bioenergetics, Redox Homeostasis, and Neurovascular Repair · 2026 · DOI

  • Limited understanding of the mechanisms by which cell therapy restores metabolic homeostasis. Need for further research to fully elucidate the potential of cell therapy for ischemic stroke. Substantial phenotypic heterogeneity of cell therapy.

    Cell Therapy as Metabolic Rescue after Ischemic Stroke: Rewiring Bioenergetics, Redox Homeostasis, and Neurovascular Repair · 2026 · DOI

  • The limitations of the present study include the small number of animals used to analyze the effect of the test substances on the levels of the proteins of interest (n = 5 in each group); a fi xed observation period – changes were assessed only 24 h after drug administration; the study was conducted in two stages: fi rst, the pharmaco- logical effect of Mexidol was assessed, then the activity of Cortexin and Cerebrolysin.

    The Effect of Neuroprotectors on BDNF, Tumor Necrosis Factor Alpha, and Apoptosis Marker Levels in Acute Cerebrovascular Accidents · 2026 · DOI

  • The evidence base remains incomplete for a definitive personalized-medicine recommendation. Much supportive evidence comes from amyloid transgenic models or non-APOE genotype rodents. The strongest APOE-genotyped evidence involves combination therapy in hypertensive older adults.

    Telmisartan for Apolipoprotein E ε4 Carriers as a Candidate Precision Medicine Strategy in Alzheimer’s Disease · 2026 · DOI

  • However, to what extent small-diameter changes in proximal capillaries alter hydrody- namic resistance, CBF or RBC fluxes needs to be further investigated. We identify a previously underrecognized function within the ACT zone that equalizes perfusion through pressure-sensitive pericyte regulation of local resistance.

    Pericyte KATP channel hyperactivity redistributes cortical blood flow in a CADASIL mouse model · 2026 · DOI

Most-cited papers in Neurological Disease Mechanisms and Treatments

Most recent work

Find a gap in your own Neurological Disease Mechanisms and Treatments sub-topic

This page shows what the Neurological Disease Mechanisms and Treatments literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Neuroscience

Autism Spectrum Disorder Research
959 open questions
Neural and Behavioral Psychology Studies
336 open questions
Functional Brain Connectivity Studies
258 open questions
Memory Processes and Influences
241 open questions
Neurobiology of Language and Bilingualism
219 open questions
Hearing Loss and Rehabilitation
218 open questions
EEG and Brain-Computer Interfaces
187 open questions
Neuroscience and Music Perception
183 open questions
52 open questions have been extracted from the limitations and future-work passages of 214 Neurological Disease Mechanisms and Treatments papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.